Cerecor Inc (CERC) Insider Purchases $30,360.00 in Stock

Cerecor Inc (NASDAQ:CERC) insider Simon Pedder purchased 6,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The shares were acquired at an average price of $5.06 per share, for a total transaction of $30,360.00. Following the completion of the transaction, the insider now owns 6,000 shares in the company, valued at $30,360. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

CERC traded up $0.11 during mid-day trading on Friday, reaching $5.37. The stock had a trading volume of 52,149 shares, compared to its average volume of 87,163. The company has a current ratio of 0.95, a quick ratio of 0.91 and a debt-to-equity ratio of 0.62. Cerecor Inc has a 52 week low of $2.71 and a 52 week high of $7.65.

Cerecor (NASDAQ:CERC) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.03. The firm had revenue of $5.41 million for the quarter, compared to analyst estimates of $4.85 million. Cerecor had a negative return on equity of 120.67% and a negative net margin of 226.50%. Research analysts anticipate that Cerecor Inc will post -0.72 earnings per share for the current fiscal year.

A number of research firms recently commented on CERC. BidaskClub upgraded Cerecor from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 1st. HC Wainwright began coverage on Cerecor in a research report on Monday, April 1st. They set a “buy” rating and a $11.00 price target on the stock. ValuEngine lowered Cerecor from a “strong-buy” rating to a “buy” rating in a research report on Thursday, March 7th. TheStreet upgraded Cerecor from a “d” rating to a “c-” rating in a research report on Wednesday, January 30th. Finally, Maxim Group began coverage on Cerecor in a research report on Tuesday, April 9th. They set a “buy” rating and a $10.00 price target on the stock. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Cerecor currently has a consensus rating of “Buy” and a consensus price target of $9.67.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Opaleye Management Inc. boosted its position in Cerecor by 5.2% in the 1st quarter. Opaleye Management Inc. now owns 2,300,000 shares of the company’s stock valued at $13,432,000 after buying an additional 114,464 shares during the last quarter. Prosight Management LP bought a new position in Cerecor in the 4th quarter valued at $994,000. Geode Capital Management LLC lifted its stake in shares of Cerecor by 50.7% in the 4th quarter. Geode Capital Management LLC now owns 94,990 shares of the company’s stock valued at $306,000 after purchasing an additional 31,951 shares during the period. Vanguard Group Inc lifted its stake in shares of Cerecor by 10.1% in the 3rd quarter. Vanguard Group Inc now owns 87,929 shares of the company’s stock valued at $411,000 after purchasing an additional 8,094 shares during the period. Finally, Spark Investment Management LLC lifted its stake in shares of Cerecor by 60.5% in the 1st quarter. Spark Investment Management LLC now owns 83,000 shares of the company’s stock valued at $484,000 after purchasing an additional 31,290 shares during the period. Hedge funds and other institutional investors own 50.28% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Cerecor Inc (CERC) Insider Purchases $30,360.00 in Stock” was originally published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.baseballdailydigest.com/news/2019/05/18/cerecor-inc-cerc-insider-purchases-30360-00-in-stock.html.

About Cerecor

Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device.

Featured Story: Find a Trading Strategy That Works

Insider Buying and Selling by Quarter for Cerecor (NASDAQ:CERC)

Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.